- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01195571
Safety Study of Four Chimera Cytomegalovirus (CMV) Vaccines in Healthy Adult Males 30-50 Years of Age
A Dose Escalation Study to Assess the Safety and Immunogenicity of Four Live Attenuated Human Cytomegalovirus(HCMV) Vaccines in Healthy Adults Without Prior Immunity.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
a) Healthy male adult, between the ages of 30 to 50 years with no children <18 years of age at home and in a stable sexual or household relationship with an individual who must be CMV seropositive, non-pregnant, not planning a pregnancy within one year and not currently breastfeeding.
b) HCMV seronegative. c) HIV seronegative. d) Hepatitis B surface antigen negative. e) No evidence of active hepatitis C infection by serologic evaluation. f) HCMV culture negative (to be determined by shell vial or routine culture of urine, blood and saliva collected at the screening visit).
g) Agrees to abstain from sex or to use condoms during intercourse for 52 weeks following vaccination.
h) Available by telephone or pager for one year following vaccination. i) Willing and able to comply with the requirements of the protocol and to properly complete participant diaries.
j) Signed informed consent and completed social/demographic questionnaire. k) Willing to forego blood, bone marrow or whole organ donation for 1year post vaccination.
l) Willing to forego enrollment in studies of other investigational agents for one year following vaccination.
Exclusion Criteria:
- History of immunodeficiency or any ongoing serious disease such as cancer, autoimmune disease, HIV infection, chronic renal failure (whether or not on dialysis), or diabetes.
- Significant acute or chronic infection at the time of vaccination.
- Household contact with an immunosuppressed individual.
- History of anaphylaxis or severe vaccine reaction.
- Vaccination with a live vaccine within the past month or an inactivated vaccine within two weeks prior to vaccination, or plan to receive any vaccine within two months following vaccination.
- Seropositive sexual partner who desires to become pregnant within one year following vaccination, currently is pregnant, or is currently breast feeding.
- Has a close contact who is CMV seronegative or who is ineligible or chooses not to participate in the study.
- Received blood products in proceeding three months or expects to receive blood products within the following year.
- A childcare provider.
- A health care provider who routinely comes in contact with pregnant women or immunologically compromised persons.
- Any condition which, in the opinion of the investigator, may interfere with adherence to the protocol or make it inadvisable to enroll the participant.
- Currently participating in a study of any other experimental or investigational agent, or has participated in such a study within a month of vaccination.
- Previous vaccination with an investigational HCMV vaccine.
- Treatment with excluded antiviral or immunosuppressive drugs (Appendix D) within one month prior to vaccination.
- Expected use of antiviral or immunosuppressive agents within two months following vaccination.
Any screening safety laboratory value that is outside normal limits of the laboratory normal range (screening laboratory tests may be repeated if minor abnormalities or possible laboratory errors are noted).
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: vaccine administration
Each subject will receive on of four chimera CMV vaccines
|
dose escalation study of 4 towne-toledo chimera vaccines
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety
Time Frame: 2 years
|
To evaluate the safety and tolerability, in adults without prior HCMV immunity (seronegative), of four live attenuated HCMV investigational vaccines at each of three dose levels.
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stuart P Adler, MD, Virginia Commonwealth University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cytomegalovirus
-
University of Alabama at BirminghamEunice Kennedy Shriver National Institute of Child Health and Human Development...RecruitingMaternal Cytomegalovirus Infections | Cytomegalovirus CongenitalUnited States
-
ModernaTX, Inc.Active, not recruitingCytomegalovirusUnited Kingdom, United States, Canada
-
University of Wisconsin, MadisonCompleted
-
University Hospital, LimogesCompleted
-
University of Sao Paulo General HospitalCompletedCytomegalovirus DiseaseBrazil
-
Mayo ClinicCompletedCytomegalovirus InfectionUnited States
-
University Hospital, LimogesCompleted
-
The George Washington University Biostatistics...Eunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedCongenital Cytomegalovirus Infection | Maternal Cytomegalovirus InfectionUnited States
-
Merck Sharp & Dohme LLCCompletedCytomegalovirus InfectionUnited States, France, Germany, Italy, Japan, United Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedCongenital Cytomegalovirus InfectionFrance
Clinical Trials on cmv vaccine
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingHematopoietic Cell Transplant Recipient | Cytomegaloviral InfectionUnited States
-
Charlotte LemechThe University of New South WalesNot yet recruiting
-
University of California, San FranciscoVicalCompletedCytomegalovirus Infection
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedNonneoplastic ConditionUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditionsUnited States
-
Masonic Cancer Center, University of MinnesotaCompletedLymphoma | Multiple MyelomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedCytomegalovirus Infection | Healthy, no Evidence of DiseaseUnited States
-
Daniel LandiPediatric Brain Tumor Foundation; Annias Immunotherapeutics, Inc.Active, not recruitingMalignant Glioma | Recurrent Medulloblastoma | Recurrent Brain Tumor, ChildhoodUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCytomegalovirus InfectionsUnited States